Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities

International Journal of Hematology

Volumn 92, Issue 2, 2010, Pages 342-350

  Lee, Sung Eun ^a   Kim, Hee Je ^a   Min, Woo Sung ^a   Cho, Byung Sik ^a   Eom, Ki Seong ^a   Kim, Yoo Jin ^a   Min, Chang Ki ^a   Lee, Seok ^a   Cho, Seok Goo ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Park, Chong Won ^a   Kim, Chun Choo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acute myelogenous leukemia; Allogeneic stem cell transplantation; Co morbidities; Old age; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; ITRACONAZOLE; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; COMORBIDITY; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; WHOLE BODY RADIATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; COMORBIDITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 77956907211     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0649-y     Document Type: Article

References (23)

1. J Finke A Nagler 2007 Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning-is there still an upper age limit? A focus on myeloid neoplasia Leukemia 21 1357 1362 1:CAS:528:DC%2BD2sXms1Wms7c%3D 10.1038/sj.leu.2404741 17508002 (Pubitemid 46969869)
2. CF Craddock 2008 Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML Bone Marrow Transplant 41 415 423 1:STN:280:DC%2BD1c7nsVymsA%3D%3D 10.1038/sj.bmt.1705975 18209726 (Pubitemid 351386707)
3. Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years? Hematology Am Soc Hematol Educ Program 2005:384-9.
4. D Valcarcel R Martino 2007 Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia Curr Opin Oncol 19 660 666 10.1097/CCO.0b013e3282f0e188 17906468 (Pubitemid 47515208)
5. R Kojima M Kami Y Kanda E Kusumi Y Kishi Y Tanaka, et al. 2005 Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years Bone Marrow Transplant 36 667 674 1:STN:280:DC%2BD2MritleksQ%3D%3D 10.1038/sj.bmt.1705122 16113674 (Pubitemid 41518708)
6. U Hegenbart D Niederwieser BM Sandmaier MB Maris JA Shizuru H Greinix, et al. 2006 Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors J Clin Oncol 24 444 453 1:CAS:528: DC%2BD28XhsFSku7k%3D 10.1200/JCO.2005.03.1765 16344316 (Pubitemid 46630463)
7. M Markova JN Barker JS Miller M Arora JE Wagner LJ Burns, et al. 2007 Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial Bone Marrow Transplant 39 193 199 1:CAS:528:DC%2BD2sXhsV2isL0%3D 10.1038/sj.bmt.1705556 17220905
8. JA Russell ML Savoie A Balogh AR Turner L Larratt MA Chaudhry, et al. 2007 Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 cGy total-body irradiation, and thymoglobulin Biol Blood Marrow Transplant 13 814 821 1:CAS:528:DC%2BD2sXosVKmur4%3D 10.1016/j.bbmt.2007.03.003 17580259 (Pubitemid 46902436)
9. Y Onishi S Mori S Kusumoto K Sugimoto D Akahane Y Morita-Hoshi, et al. 2007 Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation Int J Hematol 85 256 263 10.1532/IJH97.06199 17483064 (Pubitemid 46686587)
10. Y Belkacemi M Labopin C Hennequin S Hoffstetter R Mungai M Wygoda, et al. 2007 Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: experience from the European group for blood and marrow transplantation Int J Radiat Oncol Biol Phys 67 544 551 17141976
11. ML Sorror S Giralt BM Sandmaier M De Lima M Shahjahan DG Maloney, et al. 2007 Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences Blood 110 4606 4613 1:CAS:528:DC%2BD1cXot1en 10.1182/blood-2007-06-096966 17873123 (Pubitemid 351377830)
12. HJ Kim WS Min BS Cho KS Eom YJ Kim CK Min, et al. 2009 Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia Biol Blood Marrow Transplant 15 704 717 1:CAS:528:DC%2BD1MXotVert7c%3D 10.1016/j.bbmt.2009.02.010 19450755
13. AH Filipovich D Weisdorf S Pavletic G Socie JR Wingard SJ Lee, et al. 2005 National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report Biol Blood Marrow Transplant 11 945 956 10.1016/j.bbmt.2005.09.004 16338616 (Pubitemid 41754712)
14. M Aoudjhane M Labopin NC Gorin A Shimoni T Ruutu HJ Kolb, et al. 2005 Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the acute leukemia working party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT) Leukemia 19 2304 2312 1:CAS:528:DC%2BD2MXht1ems7bN 10.1038/sj.leu.2403967 16193083 (Pubitemid 41748028)
15. M Takahata S Hashino K Okada M Onozawa K Kahata J Sugita, et al. 2010 Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients Am J Hematol 85 243 248 1:CAS:528:DC%2BC3cXls12ltbo%3D 10.1002/ajh.21630 20162540
16. Savoie ML, Balogh A, Chaudhry A, Stewart DA, Bahlis NJ, Storek J, et al. Total body irradiation (TBI) added to fludarabine/busulfan/antithymocyte globulin (FLUBUP/ATG) conditioning increases overall survival and relapse-free survival in patients with acute myeloid leukemia (AML) receiving allogeneic stem cell transplants. ASH Annu Meet Abstr 2006;108:3010.
17. JA Russell HT Tran D Quinlan A Chaudhry P Duggan C Brown D Stewart, et al. 2002 Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes Biol Blood Marrow Transplant 8 9 468 476 1:CAS:528: DC%2BD38Xot1Ggsrc%3D 10.1053/bbmt.2002.v8.pm12374451 12374451
18. HJ Deeg BE Storer M Boeckh PJ Martin JS McCune D Myerson S Heimfeld, et al. 2006 Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen Biol Blood Marrow Transplant 12 5 573 584 1:CAS:528:DC%2BD28Xltlart70%3D 10.1016/j.bbmt.2005.12.036 16635793 (Pubitemid 43956362)
19. A Bacigalupo T Lamparelli P Bruzzi S Guidi PE Alessandrino P di Bartolomeo R Oneto, et al. 2001 Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) Blood 98 10 2942 2947 1:CAS:528:DC%2BD3MXosFyns7k%3D 10.1182/blood.V98.10.2942 11698275
20. Z Wang ML Sorror W Leisenring G Schoch DG Maloney BM Sandmaier, et al. 2010 The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation Br J Haematol 149 101 110 1:CAS:528:DC%2BC3cXltF2ltL4%3D 10.1111/j.1365-2141.2009. 08073.x 20067562
21. Blin N, Traineau R, Houssin S, de Latour RP, Petropoulo A, Robin M, et al. Impact of donor/recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant. 2010. doi: 10.1016/j.bbmt.2010.03.021 [Epub ahead of print].
22. R Cairoli A Beghini G Grillo G Nadali F Elice CB Ripamonti, et al. 2006 Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study Blood 107 3463 3468 1:CAS:528:DC%2BD28Xkt1Git7Y%3D 10.1182/blood-2005-09-3640 16384925
23. JE Rubnitz SC Raimondi AR Halbert X Tong DK Srivastava BI Razzouk, et al. 2002 Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience Leukemia 16 2072 2077 1:STN:280:DC%2BD38vpsFKqsw%3D%3D 10.1038/sj.leu.2402633 12357359 (Pubitemid 35203450)